Horizons in Cancer Research -

Horizons in Cancer Research

Volume 65

Hiroto S Watanabe (Herausgeber)

Buch | Hardcover
180 Seiten
2017
Nova Science Publishers Inc (Verlag)
978-1-5361-0944-3 (ISBN)
319,95 inkl. MwSt
This book presents original results on the leading edge of cancer research. Chapter One provides a comprehensive discussion to address the potential benefits of myricetin on cancer, diabetes, and neurodegenerative disease. It also discusses the underlined mechanism involved in the biological action of myricetin. Chapter Two discusses the clinical significance of vasculogenic mimicry. Chapter Three studies bacterial toxins as a direct cause of cancer. Chapter Four examines the immunological aspect of stroma in ovarian cancer. Chapter Five focuses on immune checkpoint inhibitors in the treatment of solid tumors. Chapter Six provides a review of targeting non-coding mitochondrial RNAs in gynecological and urinary malignancies. Chapter Seven explores the NF- B signaling pathway, and its targeting in human cancer treatment. Chapter Eight analyses the circadian rhythm and skin cancer prevention. The final section of this book is a short commentary on melanoma.

For Complete Table of Contents, please visit our website at: https://www.novapublishers.com/catalog/product_info.php?products_id=61153

Erscheinungsdatum
Verlagsort New York
Sprache englisch
Maße 155 x 230 mm
Gewicht 446 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
ISBN-10 1-5361-0944-4 / 1536109444
ISBN-13 978-1-5361-0944-3 / 9781536109443
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Hannes Leischner

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00

von Stein Husebø; Gebhard Mathis; Eva Katharina Masel

Buch | Softcover (2023)
Springer (Verlag)
49,99